Jerusalem, Israel

Elza Snir

This inventor holds 1 USPTO granted patent. Top assignee: Bioimmunate Technologies Ltd.. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Elza Snir: Innovator in Biological Filtering Technologies

Introduction

Elza Snir is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of biological filtering technologies, particularly in the context of medical applications. His innovative work focuses on developing solutions for the removal of pathogenic cells associated with diseases.

Latest Patents

Elza Snir holds a patent for a "Filter for removal of multiple sclerosis-associated t-cells." This invention describes biological filters designed to remove target components from biological fluids. The filters utilize a medium with an inert surface, featuring capture material that selectively recognizes and captures pathogenic cells. This technology has potential applications in treating autoimmune diseases and cancer.

Career Highlights

Throughout his career, Elza has been dedicated to advancing medical technologies. His work at Bioimmunate Technologies Ltd. has positioned him as a key player in the development of innovative solutions for health-related challenges. His patent reflects his commitment to improving patient outcomes through scientific innovation.

Collaborations

Elza collaborates with notable colleagues, including Sigalit Carmel and Shimon Shteingart. Their combined expertise contributes to the advancement of their projects and the overall mission of their company.

Conclusion

Elza Snir's contributions to biological filtering technologies exemplify the impact of innovation in the medical field. His work not only addresses critical health issues but also paves the way for future advancements in treatment methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…